Issue navigation
Volume 28, Issue Supplement_1, February 2022
Abstracts from the 2022 Crohn’s & Colitis Congress® held January 20–22, 2022
Quality of Life/Psychosocial Care (continued)
PEOPLE WITH IBD WANT TO TALK ABOUT SLEEP: RECOMMENDATIONS ON WHAT TO ASK AND HOW TO RESPOND TO SLEEP COMPLAINTS
Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Page S93, https://doi.org/10.1093/ibd/izac015.150
PREVALENCE AND IMPACTS OF POST-TRAUMATIC STRESS SYMPTOMS IN IBD PATIENTS FROM UNDER-REPRESENTED MINORY GROUPS
Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Pages S93–S94, https://doi.org/10.1093/ibd/izac015.151
PROMOTING AT-HOME DISEASE MANAGEMENT OF IBD WITH A MULTIDISCIPLINARY DIGITAL THERAPY APP: SHORT-TERM RESULTS
Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Page S94, https://doi.org/10.1093/ibd/izac015.152
REDEFINING HEALTHCARE: A NOVEL, SCIENCE-BASED, EXPERIENTIAL FRAMEWORK FOR IMPROVING PATIENT OUTCOMES IN INFLAMMATORY BOWEL DISEASE
Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Pages S94–S95, https://doi.org/10.1093/ibd/izac015.153
SELF-RATED HEALTH IN INFLAMMATORY BOWEL DISEASE CORRELATES WITH ANXIETY, DEPRESSION, CATASTROPHIC THINKING, AND DISEASE SEVERITY
Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Pages S95–S96, https://doi.org/10.1093/ibd/izac015.154
SEXUAL DYSFUNCTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Page S96, https://doi.org/10.1093/ibd/izac015.155
STIGMA INTERNALIZATION IN NON-WHITE PATIENTS WITH IBD AND ITS RELATIONSHIP WITH PATIENT OUTCOMES
Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Pages S96–S97, https://doi.org/10.1093/ibd/izac015.156
STIGMA PERCEPTIONS IN NON-WHITE IBD PATIENTS AND RELATIONSHIPS WITH PATIENT OUTCOMES
Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Page S97, https://doi.org/10.1093/ibd/izac015.157
THE CROHN’S AND COLITIS DISTRESS SCALE: ASSESSING THE DOMAINS OF IMPACT IN YOUTH WITH IBD
Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Page S97, https://doi.org/10.1093/ibd/izac015.158
TRANSPORTATION ACCESS AND DELAY IN DIAGNOSIS FOR PEDIATRIC INFLAMMATORY BOWEL DISEASE PATIENTS
Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Page S98, https://doi.org/10.1093/ibd/izac015.159
Therapeutic Drug Monitoring
BIOLOGIC PRECISION DOSING IS NOW AVAILABLE AT THE BEDSIDE FOR CHILDREN AND ADULTS WITH INFLAMMATORY BOWEL DISEASE RECEIVING INFLIXIMAB
Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Pages S98–S99, https://doi.org/10.1093/ibd/izac015.160
PREDICTIVE PERFORMANCE OF DIFFERENT POPULATION PHARMACOKINETIC MODELS IN A REAL-WORLD COHORT OF CROHN’S DISEASE PATIENTS
Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Pages S99–S100, https://doi.org/10.1093/ibd/izac015.161
REAL-WORLD VEDOLIZUMAB PHARMACOKINETIC STUDY IN CHILDREN IDENTIFIES TWO NOVEL BIOMARKERS OF DRUG CLEARANCE
Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Page S100, https://doi.org/10.1093/ibd/izac015.162
Uncontrolled Therapeutic Observations in Humans Using Biologic or Non-Biologic Agents
AN ONLINE SURVEY AMONG US PATIENTS WITH IMMUNE-MEDIATED CONDITIONS: BELIEFS ABOUT BIOSIMILARS FROM PATIENTS WITH INFLAMMATORY BOWEL DISEASE
Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Page S101, https://doi.org/10.1093/ibd/izac015.163
ANTI-SARS-COV-2 VACCINATION AND ANTIBODY RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE ON IMMUNE-MODIFYING THERAPY. PROSPECTIVE SINGLE TERTIARY CENTER STUDY ON 602 IBD PATIENTS
Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Pages S101–S102, https://doi.org/10.1093/ibd/izac015.164
BEZLOTOXUMAB THERAPY FOR RECURRENT CLOSTRIDIUM DIFFICILE INFECTION IN AN ULCERATIVE COLITIS PATIENT
Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Page S102, https://doi.org/10.1093/ibd/izac015.165
BIOLOGICAL THERAPY AND POST-OPERATIVE OUTCOMES IN CROHN’S DISEASE PATIENTS UNDERGOING REPEAT ILEOCOLIC RESECTION
Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Pages S102–S103, https://doi.org/10.1093/ibd/izac015.166
COMBINATION BIOLOGIC AND SMALL MOLECULE THERAPY FOR REFRACTORY ULCERATIVE COLITIS
Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Page S103, https://doi.org/10.1093/ibd/izac015.167
COMBINATION USTEKINUMAB AND VEDOLIZUMAB THERAPY FOR REFRACTORY INFLAMMATORY BOWEL DISEASE: A SINGLE INSTITUTION CASE SERIES
Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Pages S103–S104, https://doi.org/10.1093/ibd/izac015.168
COVID-19 INFECTIONS IN VACCINATED PATIENTS WITH INFLAMMATORY BOWEL DISEASE: OUTCOMES AND RISK FACTORS FOR SEVERE DISEASE
Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Pages S104–S105, https://doi.org/10.1093/ibd/izac015.169
DUAL BIOLOGICAL OR SMALL MOLECULE TREATMENT IN INFLAMMATORY BOWEL DISEASES: DATA FROM CLINICAL PRACTICE
Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Page S105, https://doi.org/10.1093/ibd/izac015.170
EARLY VERSUS DELAYED INITIATION OF VEDOLIZUMAB IN ULCERATIVE COLITIS: TREATMENT RESPONSE IN THE REAL WORLD (RALEE)
Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Pages S105–S106, https://doi.org/10.1093/ibd/izac015.171
EFFICACY OF LOW DOSE NALTREXONE IN PATIENTS WITH CROHN’S COLITIS AND ILEITIS
Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Pages S106–S107, https://doi.org/10.1093/ibd/izac015.172
HIGH DOSE TOFACITINIB AS SALVAGE THERAPY IN STEROID REFRACTORY ACUTE SEVERE ULCERATIVE COLITIS FOLLOWING NON-RESPONSE TO INFLIXIMAB
Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Page S107, https://doi.org/10.1093/ibd/izac015.173
IMPACT OF THIOPURINE DOSE IN COMBINATION THERAPY IN INFLAMMATORY BOWEL DISEASE
Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Pages S107–S108, https://doi.org/10.1093/ibd/izac015.174
REAL WORLD EFFECTIVENESS AND SAFETY OF OZANIMOD: INITIAL RESULTS FROM A LARGE TERTIARY CENTER
Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Page S109, https://doi.org/10.1093/ibd/izac015.175
REAL-WORLD UTILIZATION OF ADALIMUMAB BIOSIMILAR (ABP 501) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN EUROPE
Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Pages S109–S110, https://doi.org/10.1093/ibd/izac015.176
SUCCESSFUL CLEARANCE OF CYTOMEGALOVIRUS COLITIS IN ACUTE SEVERE ULCERATIVE COLITIS DURING INDUCTION OF OZANIMOD
Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Pages S110–S111, https://doi.org/10.1093/ibd/izac015.177
VEDOLIZUMAB AS TREATMENT FOR COMMON VARIABLE IMMUNE DEFICIENCY (CVID): A CASE SERIES AND BRIEF REVIEW OF THE LITERATURE
Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Page S111, https://doi.org/10.1093/ibd/izac015.178
VEDOLIZUMAB FOR REFRACTORY MICROSCOPIC COLITIS: A CASE SERIES
Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Page S112, https://doi.org/10.1093/ibd/izac015.179
WITHDRAWN: EFFICACY, SAFETY, AND TOLERABILITY OF OMILANCOR IN A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PATIENTS WITH ULCERATIVE COLITIS
Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Page S112, https://doi.org/10.1093/ibd/izac015.180
